Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C mutation.
Publication/Presentation Date
8-27-2025
Abstract
Metastatic ovarian cancer patients who have recurrent disease after multiple lines of prior treatment have dismal prognosis. The Kristen rat sarcoma viral oncogene homologue (
Volume
18
Issue
8
ISSN
1757-790X
Published In/Presented At
Mani, H., & Nair, S. (2025). Sotorasib provides a durable response in high-grade metastatic ovarian serous adenocarcinoma harbouring KRAS G12C mutation. BMJ case reports, 18(8), e266618. https://doi.org/10.1136/bcr-2025-266618
Disciplines
Medicine and Health Sciences
PubMedID
40866105
Department(s)
Department of Medicine, Hematology-Medical Oncology Division, Lehigh Valley Topper Cancer Institute
Document Type
Article
COinS